Drugs / IN001
IN001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06375512 | Jul 2024 → Feb 2026 | herpes zoster | Shenzhen Shenxin Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07205796 | May 2026 → Dec 2027 expected | herpes zoster | Shenzhen Shenxin Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06375512 ↗ |
| Known as | Herpes Zoster IN001 mRNA Vaccine | “A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants” NCT07205796 ↗ |
| Known as | HZ Vaccine (IN001) | “Biological: HZ Vaccine (IN001)” NCT07205796 ↗1“Biological: HZ Vaccine (IN001)” NCT06375512 ↗ |
| Modality | Messenger RNA (mRNA) | “Herpes Zoster IN001 mRNA Vaccine (IN001)” NCT06375512 ↗ |
| Route | Intramuscular | “Participants will receive IN001 by IM injection on Day 0 and Day 56.” NCT06375512 ↗ |